A temporally resolved CRISPR-Cas9 screen reveals DAC-induced DNA damage drives trans-cell cycle cytotoxicity that depends on ...

The Madison Re-Prom is returning to the Monona Terrace this February for its 13th year. The annual gala brings grown ups back ...

Myriad Genetics announces USPTO grants two new patents for its molecular residual disease assay: Salt Lake City Friday, February 7, 2025, 13:00 Hrs [IST] Myriad Genetics, Inc., a ...

Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic and tumor genomic testing and precision medicine, announced that the United States Patent and ...

Three patients with spinal muscular atrophy had improved muscle strength and could walk farther after a month of daily spinal ...

Electrical stimulation of the spinal cord strengthened the muscles of three people with spinal muscular atrophy, a rare motor neuron disease.

Myriad Genetics (MYGN) announced that the United States Patent and Trademark Office has issued two new patents that further advance Myriad’s ability to bring its tumor-informed, high-definition, ...

Q4 2024 Earnings Call Transcript February 4, 2025 Operator: Hello, and welcome to Regeneron Pharmaceuticals Fourth Quarter ...

A recent study co-authored by Bucknell University Professor Chris Martine, biology, David Burpee Professor in Plant Genetics ...

HDYO released data from recent surveys of the global HD community. Learn more about the findings and how surveys can help ...

A little more than a third (36.1%) of patients with Huntington disease (HD) and chorea are taking an anti-chorea medication, a study found.